Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States

Epilepsy Research

Volumn 73, Issue 3, 2007, Pages 275-283

  Dutta, Sandeep ^a   Reed, Ronald C ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Absorption; Oral formulations; Pharmacokinetics; Valproate; VPA

Indexed keywords

VALPROATE SEMISODIUM; VALPROIC ACID;

AREA UNDER THE CURVE; ARTICLE; CAPSULE ENDOSCOPE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG RELEASE; ENTERIC COATED TABLET; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; UNITED STATES;

ABSORPTION; ADMINISTRATION, ORAL; ANTICONVULSANTS; AREA UNDER CURVE; DRUG COMBINATIONS; DRUG COMPOUNDING; EPILEPSY; HUMANS; UNITED STATES; VALPROIC ACID;

EID: 33847179879     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2006.11.005     Document Type: Article

References (18)

1. ® Sprinkle). J. Clin. Pharmacol. 30 8 (1990) 743-747
2. Cavanaugh J.H., Granneman R., Lamm J., et al. Effect of food on the bioavailability of a controlled-release formulation of Depakote under multiple-dose conditions. Epilepsia 38 Suppl. 8 (1997) 54
3. Chun A.H., Hoffman D.J., Friedmann N., et al. Bioavailability of valproic acid under fasting/nonfasting regimens. J. Clin. Pharmacol. 20 1 (1980) 30-36
4. Cloyd J.C., Kriel R.L., Jones-Saete C.M., et al. Comparison of sprinkle versus syrup formulations of valproate for bioavailability, tolerance, and preference. J. Pediatr. 120 4, Pt. 1 (1992) 634-638
5. ® Valproic Acid Capsules and Syrup. Abbott Laboratories, Inc., North Chicago, IL, USA.
6. ® ER Tablets Product Information, 2005. Divalproex Sodium Extended-Release Tablets. Abbott Laboratories, Inc., North Chicago, IL, USA.
7. ® Sprinkle Capsules Product Information, 2003. Divalproex Sodium Coated Particles in Capsules. Abbott Laboratories, Inc., North Chicago, IL, USA.
8. ® Tablets Product Information, 2004. Divalproex Sodium Delayed-Release Tablets. Abbott Laboratories, Inc., North Chicago, IL, USA.
9. Dutta S., Reed R.C., and Cavanaugh J.H. Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers. J. Clin. Pharmacol. 44 7 (2004) 737-742
10. Dutta S., and Zhang Y. Bioavailability of divalproex extended-release formulation relative to the divalproex delayed-release formulation. Biopharm. Drug Dispos. 25 8 (2004) 345-352
11. Dutta S., and Reed R.C. Divalproex to divalproex extended release conversion. Clin. Drug Invest. 24 9 (2004) 495-508
12. Dutta S., Zhang Y., Lee L.L., and O'Dea R. Comparison of the bioavailability of 250 and 500 mg divalproex sodium extended-release tablets in healthy volunteers. Biopharm. Drug Dispos. 25 8 (2004) 353-357
13. Dutta S., and Reed R.C. Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets - Clinical implications. Ann. Pharmacother. 40 (2006) 619-625
14. Dutta S., and Reed R.C. A multiphasic absorption model best characterizes gastrointestinal absorption of divalproex sodium extended-release tablets. J. Clin. Pharmacol. 46 (2006) 952-957
15. FDA Orange Book, 2006. http://www.accessdata.fda.gov/scripts/cder/ob/docs/tempai.cfm, keywords "valproic acid" and "divalproex", accessed March 27.
16. Fischer J.H., Barr A.N., Paloucek F.P., et al. Effect of food on the serum concentration profile of enteric-coated valproic acid. Neurology 38 8 (1988) 1319-1322
17. Gibaldi M., and Perrier D. Pharmacokinetics. 2nd ed. (1982), Marcel Dekker, New York
18. Hussein Z., Mukherjee D., Lamm J., et al. Pharmacokinetics of valproate after multiple-dose oral and intravenous infusion administration: gastrointestinal-related diurnal variation. J. Clin. Pharmacol. 34 7 (1994) 754-759